Radafaxine: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{wikify}} |
{{wikify}} |
||
'''Radafaxine''' is a [[drug]] currently in development by [[GlaxoSmithKline]]. Presently in various [[clinical trials]], Radafaxine is being studied as a treatment for [[clinical depression]], [[obesity]], and [[neuropathy|neuropathic pain]]. Radafaxine is described as a [[norepinephrine-dopamine reuptake inhibitor]] (NDRI). It is a potent metabolite of bupropion, the compound in GlaxoSmithKline's [[Wellbutrin]]. Therefore, Radafaxine builds on at least some of the properties of bupropion in humans. [http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=105&STORY=/www/story/11-23-2004/0002499330] |
'''Radafaxine''' is a [[drug]] currently in development by [[GlaxoSmithKline]]. Presently in various [[clinical trials]], Radafaxine is being studied as a treatment for [[clinical depression]], [[obesity]], and [[neuropathy|neuropathic pain]]. Radafaxine is described as a [[norepinephrine-dopamine reuptake inhibitor]] (NDRI). It is a potent [[Metabolite#Metabolites|metabolite]] of bupropion, the compound in GlaxoSmithKline's [[Wellbutrin]]. Therefore, Radafaxine builds on at least some of the properties of bupropion in humans. [http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=105&STORY=/www/story/11-23-2004/0002499330] |
||
Unlike [[bupropion]] (which has a slightly higher effect on [[dopamine]] [[reuptake]]), Radafaxine seems to have a higher potentcy on [[norepinephrine]]. This, according to GlaxoSmithKline, may account for the increased effect of Radafaxine on [[pain]] and [[Fatigue (medical)|fatigue]].[http://213.219.8.102/pdfs/gsk/cns_seminar/353162.pdf] |
Unlike [[bupropion]] (which has a slightly higher effect on [[dopamine]] [[reuptake]]), Radafaxine seems to have a higher potentcy on [[norepinephrine]]. This, according to GlaxoSmithKline, may account for the increased effect of Radafaxine on [[pain]] and [[Fatigue (medical)|fatigue]].[http://213.219.8.102/pdfs/gsk/cns_seminar/353162.pdf] |
||
Revision as of 19:55, 9 February 2007
 | Template:Wikify is deprecated. Please use a more specific cleanup template as listed in the documentation. |
Radafaxine is a drug currently in development by GlaxoSmithKline. Presently in various clinical trials, Radafaxine is being studied as a treatment for clinical depression, obesity, and neuropathic pain. Radafaxine is described as a norepinephrine-dopamine reuptake inhibitor (NDRI). It is a potent metabolite of bupropion, the compound in GlaxoSmithKline's Wellbutrin. Therefore, Radafaxine builds on at least some of the properties of bupropion in humans. [1]
Unlike bupropion (which has a slightly higher effect on dopamine reuptake), Radafaxine seems to have a higher potentcy on norepinephrine. This, according to GlaxoSmithKline, may account for the increased effect of Radafaxine on pain and fatigue.[2]
At least one study suggests that Radafaxine has a low - abuse potential similar to bupropion.[3]
GlaxoSmithKline is targeting Radafaxine for regulatory filing in 2007. [4]